Subject matters | Details | Categories |
---|---|---|
Santé
|
Discussion of a possible Therapeutics Products Directorate ("TPD") workstream on complex generics regulatory pathways.
|
Politique ou Programme
|
Santé
|
Discussion of regulatory impediments to the launch of pediatric formulations of branded and generic products.
|
Politique ou Programme
|
Santé
|
Discussion on the opioid crisis and the Health minister's expectations from pharmaceutical manufacturers
|
Politique ou Programme
|
Développement économique, Recherche et développement, Sciences et technologies, Impôts et finances
|
Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development.
|
Politique ou Programme
|
Santé
|
Policies aimed at facilitating generic drug repurposing.
|
Politique ou Programme
|
Développement économique, Santé, Industrie
|
Policies aimed at reinforcing pharmaceutical supply chain.
|
Politique ou Programme
|
Développement économique, Santé, Industrie
|
Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
|
Subvention, Contribution ou autre avantage financier
|
Pharmascience Inc. is a Canadian-owned pharmaceutical company specializing in the manufacturing and distribution of generic, innovative, and consumer brand pharmaceutical products in Canada
Martin Arès, Chief Executive Officer
End date of the last completed financial year: 2023-05-31
Government Institution | Funding Received in Last Financial Year | Funding Expected in Current Financial Year |
---|---|---|
Innovation, Science and Economic Development Canada (ISED) | $0.00 | Yes |
Investissement Québec | $94,719.38 | Yes |
Address:
6111 Royalmount avenue, suite 100
Montreal, QC H4P 2T4
Canada
Telephone number:
514-340-9800
Pharmascience Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking